Bio-Rad Laboratories, Inc. (NYSE:BIO) EVP Giovanni Magni sold 2,400 shares of the business’s stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $253.01, for a total transaction of $607,224.00. Following the sale, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at approximately $2,340,595.51. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Bio-Rad Laboratories, Inc. (NYSE:BIO) traded down $0.77 during mid-day trading on Friday, reaching $255.49. 129,090 shares of the company traded hands, compared to its average volume of 181,539. Bio-Rad Laboratories, Inc. has a fifty-two week low of $169.19 and a fifty-two week high of $268.40. The firm has a market capitalization of $7,504.68, a price-to-earnings ratio of 80.39, a PEG ratio of 3.82 and a beta of 0.88. The company has a current ratio of 4.06, a quick ratio of 2.77 and a debt-to-equity ratio of 0.15.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, November 2nd. The medical research company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.54 by $0.37. Bio-Rad Laboratories had a net margin of 1.15% and a return on equity of 3.44%. The business had revenue of $535.00 million during the quarter, compared to analyst estimates of $507.99 million. During the same period in the prior year, the business earned $0.62 earnings per share. The business’s quarterly revenue was up 5.2% on a year-over-year basis. equities analysts forecast that Bio-Rad Laboratories, Inc. will post 2.65 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/11/17/giovanni-magni-sells-2400-shares-of-bio-rad-laboratories-inc-bio-stock.html.

Several research firms have commented on BIO. TheStreet upgraded shares of Bio-Rad Laboratories from a “c+” rating to a “b-” rating in a research report on Monday. Zacks Investment Research cut shares of Bio-Rad Laboratories from a “hold” rating to a “sell” rating in a report on Thursday, August 10th. Finally, Deutsche Bank AG reiterated a “buy” rating and issued a $255.00 price objective on shares of Bio-Rad Laboratories in a report on Monday, September 18th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and an average price target of $260.00.

A number of hedge funds have recently added to or reduced their stakes in BIO. American Century Companies Inc. acquired a new stake in Bio-Rad Laboratories during the third quarter valued at approximately $125,820,000. FMR LLC lifted its position in shares of Bio-Rad Laboratories by 237.4% in the 2nd quarter. FMR LLC now owns 711,313 shares of the medical research company’s stock valued at $160,978,000 after acquiring an additional 500,513 shares in the last quarter. Royal Bank of Canada lifted its position in shares of Bio-Rad Laboratories by 101.2% in the 2nd quarter. Royal Bank of Canada now owns 3,324 shares of the medical research company’s stock valued at $752,000 after acquiring an additional 281,264 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Bio-Rad Laboratories by 93.1% in the 2nd quarter. Wells Fargo & Company MN now owns 523,876 shares of the medical research company’s stock valued at $118,557,000 after acquiring an additional 252,643 shares in the last quarter. Finally, Cramer Rosenthal Mcglynn LLC lifted its position in shares of Bio-Rad Laboratories by 217.6% in the 2nd quarter. Cramer Rosenthal Mcglynn LLC now owns 318,942 shares of the medical research company’s stock valued at $72,180,000 after acquiring an additional 218,512 shares in the last quarter. 64.27% of the stock is owned by institutional investors and hedge funds.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.